JP2023512454A5 - - Google Patents
Info
- Publication number
- JP2023512454A5 JP2023512454A5 JP2022542670A JP2022542670A JP2023512454A5 JP 2023512454 A5 JP2023512454 A5 JP 2023512454A5 JP 2022542670 A JP2022542670 A JP 2022542670A JP 2022542670 A JP2022542670 A JP 2022542670A JP 2023512454 A5 JP2023512454 A5 JP 2023512454A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- binding domain
- terminus
- amino terminus
- carboxyl terminus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025184163A JP2026021465A (ja) | 2020-01-13 | 2025-10-31 | タンパク質治療のための製剤 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062960562P | 2020-01-13 | 2020-01-13 | |
| US62/960,562 | 2020-01-13 | ||
| US202063121633P | 2020-12-04 | 2020-12-04 | |
| US63/121,633 | 2020-12-04 | ||
| PCT/US2021/013294 WO2021146328A1 (en) | 2020-01-13 | 2021-01-13 | Formulations for protein therapeutics |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025184163A Division JP2026021465A (ja) | 2020-01-13 | 2025-10-31 | タンパク質治療のための製剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023512454A JP2023512454A (ja) | 2023-03-27 |
| JP2023512454A5 true JP2023512454A5 (enExample) | 2024-01-22 |
Family
ID=74592744
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022542670A Pending JP2023512454A (ja) | 2020-01-13 | 2021-01-13 | タンパク質治療のための製剤 |
| JP2025184163A Pending JP2026021465A (ja) | 2020-01-13 | 2025-10-31 | タンパク質治療のための製剤 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025184163A Pending JP2026021465A (ja) | 2020-01-13 | 2025-10-31 | タンパク質治療のための製剤 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230303720A1 (enExample) |
| EP (1) | EP4090367A1 (enExample) |
| JP (2) | JP2023512454A (enExample) |
| KR (1) | KR20220127843A (enExample) |
| CN (1) | CN115279406A (enExample) |
| AU (1) | AU2021207470A1 (enExample) |
| BR (1) | BR112022013725A2 (enExample) |
| CA (1) | CA3164385A1 (enExample) |
| IL (1) | IL294458A (enExample) |
| MX (1) | MX2022008654A (enExample) |
| WO (1) | WO2021146328A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3515491A4 (en) | 2016-09-21 | 2020-09-16 | Aptevo Research and Development LLC | CD123 BINDING PROTEINS AND RELATED COMPOSITIONS AND PROCESSES |
| RS67656B1 (sr) | 2018-05-10 | 2026-02-27 | Regeneron Pharma | Formulacije koje sadrže visoke koncentracije fuzionog proteina vegf receptora |
| JP7137696B2 (ja) | 2019-05-14 | 2022-09-14 | プロヴェンション・バイオ・インコーポレイテッド | １型糖尿病を予防するための方法および組成物 |
| KR20230092863A (ko) | 2020-06-11 | 2023-06-26 | 프로벤션 바이오, 인코포레이티드 | 제1형 당뇨병을 예방하기 위한 방법 및 조성물 |
| MX2023013851A (es) | 2021-05-24 | 2023-12-08 | Provention Bio Inc | Metodos para el tratamiento de diabetes tipo 1. |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5283173A (en) | 1990-01-24 | 1994-02-01 | The Research Foundation Of State University Of New York | System to detect protein-protein interactions |
| GB9518220D0 (en) | 1995-09-06 | 1995-11-08 | Medical Res Council | Checkpoint gene |
| US6440418B1 (en) | 1995-11-07 | 2002-08-27 | Idec Pharmaceuticals Corporation | Methods of treating autoimmune diseases with gp39-specific antibodies |
| US6660843B1 (en) | 1998-10-23 | 2003-12-09 | Amgen Inc. | Modified peptides as therapeutic agents |
| AU2004242846A1 (en) | 2003-05-31 | 2004-12-09 | Micromet Ag | Pharmaceutical compositions comprising bispecific anti-CD3, anti-CD19 antibody constructs for the treatment of B-cell related disorders |
| AU2004242845B2 (en) | 2003-05-31 | 2011-06-02 | Amgen Research (Munich) Gmbh | Human-anti-human CD3 binding molecules |
| US8076459B2 (en) | 2003-10-16 | 2011-12-13 | Micromet Ag | Multispecfic deimmunized CD3-binders |
| US7393662B2 (en) | 2004-09-03 | 2008-07-01 | Centocor, Inc. | Human EPO mimetic hinge core mimetibodies, compositions, methods and uses |
| CN105837690A (zh) | 2006-06-12 | 2016-08-10 | 新兴产品开发西雅图有限公司 | 具有效应功能的单链多价结合蛋白 |
| CA2665567C (en) * | 2006-10-06 | 2012-07-03 | Amgen Inc. | Stable formulations |
| PL2155788T3 (pl) | 2007-04-03 | 2013-02-28 | Amgen Res Munich Gmbh | Swoiste międzygatunkowe bispecyficzne czynniki wiążące |
| KR20110044991A (ko) | 2008-07-02 | 2011-05-03 | 이머전트 프로덕트 디벨롭먼트 시애틀, 엘엘씨 | ＴＮＦ-α 길항제 다-표적 결합 단백질 |
| MX2011003502A (es) | 2008-10-01 | 2011-09-01 | Micromet Ag | Anticuerpo de cadena sencilla biespecifica de psmaxcd3 especifico a traves de especies. |
| AU2009298131B2 (en) | 2008-10-02 | 2016-07-14 | Aptevo Research And Development Llc | CD86 antagonist multi-target binding proteins |
| US20130129723A1 (en) | 2009-12-29 | 2013-05-23 | Emergent Product Development Seattle, Llc | Heterodimer Binding Proteins and Uses Thereof |
| US20130089554A1 (en) | 2009-12-29 | 2013-04-11 | Emergent Product Development Seattle, Llc | RON Binding Constructs and Methods of Use Thereof |
| TWI653333B (zh) | 2010-04-01 | 2019-03-11 | 安進研究（慕尼黑）有限責任公司 | 跨物種專一性之ＰＳＭＡｘＣＤ３雙專一性單鏈抗體 |
| ES2667100T3 (es) | 2010-08-02 | 2018-05-09 | Macrogenics, Inc. | Diacuerpos covalentes y sus usos |
| BR112013027224A8 (pt) * | 2011-04-22 | 2018-08-14 | Emergent Product Dev Seattle | Proteínas de ligação de antígeno de membrana específico de próstata e composições e métodos relacionados |
| WO2012162067A2 (en) | 2011-05-21 | 2012-11-29 | Macrogenics, Inc. | Cd3-binding molecules capable of binding to human and non-human cd3 |
| IN2014MN02293A (enExample) | 2012-04-20 | 2015-08-07 | Emergent Product Dev Seattle | |
| WO2015200027A1 (en) * | 2014-06-26 | 2015-12-30 | Amgen Inc. | Protein formulations |
| WO2016094873A2 (en) | 2014-12-12 | 2016-06-16 | Emergent Product Development Seattle, Llc | Receptor tyrosine kinase-like orphan receptor 1 binding proteins and related compositions and methods |
| BR112017024770A2 (pt) | 2015-05-21 | 2018-07-31 | Alligator Bioscience Ab | polipeptídeos inovadores |
| HK1251480A1 (zh) | 2015-09-21 | 2019-02-01 | Aptevo Research And Development Llc | Cd3结合多肽 |
| TWI790206B (zh) * | 2016-07-18 | 2023-01-21 | 法商賽諾菲公司 | 特異性結合至ｃｄ３和ｃｄ１２３的雙特異性抗體樣結合蛋白 |
| EP3515491A4 (en) * | 2016-09-21 | 2020-09-16 | Aptevo Research and Development LLC | CD123 BINDING PROTEINS AND RELATED COMPOSITIONS AND PROCESSES |
| WO2019050521A1 (en) * | 2017-09-07 | 2019-03-14 | Macrogenics, Inc. | DOSAGE SCHEMES OF BISPECIFIC DIACORPS CD123 X CD3 IN THE TREATMENT OF HEMATOLOGICAL MALIGNANCIES |
-
2021
- 2021-01-13 CN CN202180020514.1A patent/CN115279406A/zh active Pending
- 2021-01-13 EP EP21704990.7A patent/EP4090367A1/en active Pending
- 2021-01-13 CA CA3164385A patent/CA3164385A1/en active Pending
- 2021-01-13 JP JP2022542670A patent/JP2023512454A/ja active Pending
- 2021-01-13 KR KR1020227026642A patent/KR20220127843A/ko active Pending
- 2021-01-13 BR BR112022013725A patent/BR112022013725A2/pt unknown
- 2021-01-13 US US17/802,920 patent/US20230303720A1/en active Pending
- 2021-01-13 AU AU2021207470A patent/AU2021207470A1/en active Pending
- 2021-01-13 IL IL294458A patent/IL294458A/en unknown
- 2021-01-13 MX MX2022008654A patent/MX2022008654A/es unknown
- 2021-01-13 WO PCT/US2021/013294 patent/WO2021146328A1/en not_active Ceased
-
2025
- 2025-10-31 JP JP2025184163A patent/JP2026021465A/ja active Pending